FDA Approves Krystexxa, New Treatment for Gout - DrugWatch.com

TopNews United Kingdom (blog)

FDA Approves Krystexxa, New Treatment for Gout DrugWatch.com Current medications approved for the treatment of gout include allopurinol (Aloprim, Zyloprim), colchicine (Colcrys), and febuxostat (Uloric). ... Savient shares soar on FDA gout treatment approvalMarketWatch FDA approves gout treatment from SavientDrug Store News Savient shares rally as FDA approves gout drugReuters eMaxHealth -BusinessWeek -MedPage Today all 199 news articles »

FDA Approves New Gout Treatment Krystexxa - RTT News

RTT News

FDA Approves New Gout Treatment Krystexxa RTT News "Krystexxa is the first-ever and only treatment approved by the FDA for adult patients who suffer with chronic gout that is refractory to conventional ... Savient shares Shares at a 52 week high following chatterSmall Cap Network Rumor Mill Sends Savient Pharma (SVNT) Shares SoaringStreetInsider.com (subscription) (blog) Stock Rumors of the Day (Savient Pharmaceuticals, Brocade Communications , IBM)Benzinga all 21 news articles »

BioCryst Drug Boosted Existing Gout Treatment In Study - Wall Street Journal

BioCryst Drug Boosted Existing Gout Treatment In Study Wall Street Journal The study showed the combination of BCX4208 and gout-treatment allopurinol reduced serum uric acid concentration more than either drug alone. ... BioCryst Reports Positive Results From A Phase 2 Study Of BCX4208 Combined ...MarketWatch (press release) BioCryst gout drug shows promise in mid-stage trialReuters BioCryst reports positive results for gout drugBirmingham Business Journal Stock Markets Review all 27 news articles »

Jon Najarian: Biotech Buzz In These Two Stocks - CNBC

Jon Najarian: Biotech Buzz In These Two Stocks CNBC which specializes in treatments for gout. The Monster started keeping an eye on Declath Systems after spotting a higher than unusual volume of October 8 and ... and more »